Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity

Free Radical Biology and Medicine

Volumn 57, Issue , 2013, Pages 188-200

  Asensio López, Mari C ^a   Sánchez Más, Jesús ^a   Pascual Figal, Domingo A ^a   Abenza, Sergio ^a   Pérez Martínez, María T ^a   Valdés, Mariano ^a   Lax, Antonio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Cardiotoxicity; Doxorubicin; Ferritin; Free radicals; Metformin; Oxidative stress

Indexed keywords

CATALASE; DOXORUBICIN; FERRITIN; FERRITIN HEAVY CHAIN; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOTOXICITY; CELL CULTURE; CELL DAMAGE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HEART MUSCLE CELL; HEART PROTECTION; HEAVY CHAIN; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOFERRITINS; CARDIOTOXINS; CATALASE; CELL LINE; DOXORUBICIN; ENZYME ACTIVATION; GENE EXPRESSION; GLUTATHIONE PEROXIDASE; HEART; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; MYOCYTES, CARDIAC; NF-KAPPA B; OXIDATIVE STRESS; PEPTIDES; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE;

EID: 84874658219     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.09.009     Document Type: Article

References (52)

1. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
2. UK Prospective Diabetes Study (UKPDS) Group UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes Diabetes Care 21 1998 87 92
3. M.C. Asensio-Lopez, A. Lax, D.A. Pascual-Figal, M. Valdes, and J. Sanchez-Mas Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system Free Radic. Biol. Med. 51 2011 1861 1871
4. J.M. Berthiaume, and K.B. Wallace Adriamycin-induced oxidative mitochondrial cardiotoxicity Cell Biol. Toxicol. 23 2007 15 25 (Pubitemid 44950185)
5. M.R. Bristow, M.E. Billingham, J.W. Mason, and J.R. Daniels Clinical spectrum of anthracycline antibiotic cardiotoxicity Cancer Treat. Rep 62 1978 873 879 (Pubitemid 8377881)
6. J.W. Calvert, S. Gundewar, S. Jha, J.J. Greer, W.H. Bestermann, R. Tian, and D.J. Lefer Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling Diabetes 57 2008 696 705
7. A.Y. Chan, C.L. Soltys, M.E. Young, C.G. Proud, and J.R. Dyck Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte J. Biol. Chem. 279 2004 32771 32779 (Pubitemid 39014736)
8. K. Chatterjee, J. Zhang, N. Honbo, and J.S. Karliner Doxorubicin cardiomyopathy Cardiology 115 2010 155 162
9. G. Corna, P. Santambrogio, G. Minotti, and G. Cairo Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin J. Biol. Chem. 279 2004 13738 13745 (Pubitemid 38468903)
10. A. Cozzi, B. Corsi, S. Levi, P. Santambrogio, G. Biasiotto, and P. Arosio Analysis of the biologic functions of H- and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin Blood 103 2004 2377 2383 (Pubitemid 38326261)
11. E.D. Danz, J. Skramsted, N. Henry, J.A. Bennett, and R.S. Keller Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway Free Radic. Biol. Med. 46 2009 1589 1597
12. M.S. El, G.A. Rongen, R.A. de Boer, and N.P. Riksen The cardioprotective effects of metformin Curr. Opin. Lipidol. 22 2011 445 453
13. D.T. Eurich, S.R. Majumdar, F.A. McAlister, R.T. Tsuyuki, and J.A. Johnson Improved clinical outcomes associated with metformin in patients with diabetes and heart failure Diabetes Care 28 2005 2345 2351 (Pubitemid 41384275)
14. Y.H. Feng, G. Velazquez-Torres, C. Gully, J. Chen, M.H. Lee, and S.C. Yeung The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth J. Cell Mol. Med. 15 2011 825 836
15. L. Gianni, E.H. Herman, S.E. Lipshultz, G. Minotti, N. Sarvazyan, and D.B. Sawyer Anthracycline cardiotoxicity: from bench to bedside J. Clin. Oncol. 26 2008 3777 3784
16. L. Gianni, L. Vigano, A. Locatelli, G. Capri, A. Giani, E. Tarenzi, and G. Bonadonna Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer J. Clin. Oncol. 15 1997 1906 1915 (Pubitemid 27209520)
17. F.J. Giordano Oxygen, oxidative stress, hypoxia, and heart failure J. Clin. Invest. 115 2005 500 508 (Pubitemid 40322219)
18. S. Gundewar, J.W. Calvert, S. Jha, I. Toedt-Pingel, S.Y. Ji, D. Nunez, A. Ramachandran, M. Anaya-Cisneros, R. Tian, and D.J. Lefer Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure Circ. Res. 104 2009 403 411
19. B.B. Hasinoff, and E.H. Herman Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc. Toxicol 7 2007 140 144 (Pubitemid 47339861)
20. H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis, and K. Struhl Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res. 69 2009 7507 7511
21. Y. Ikegami, K. Inukai, K. Imai, Y. Sakamoto, H. Katagiri, S. Kurihara, T. Awata, and S. Katayama Adiponectin upregulates ferritin heavy chain in skeletal muscle cells Diabetes 58 2009 61 70
22. D. Iliopoulos, H.A. Hirsch, and K. Struhl Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types Cancer Res 71 2011 3196 3201
23. H. Kaiserova, T. Simunek, M. Sterba, G.J. den Hartog, L. Schroterova, O. Popelova, V. Gersl, E. Kvasnickova, and A. Bast New iron chelators in anthracycline-induced cardiotoxicity Cardiovasc. Toxicol. 7 2007 145 150 (Pubitemid 47339862)
24. J. Kasapovic, S. Pejic, V. Stojiljkovic, A. Todorovic, L. Radosevic-Jelic, Z.S. Saicic, and S.B. Pajovic Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide Clin. Biochem. 43 2010 1287 1293
25. G. Kewalramani, P. Puthanveetil, F. Wang, M.S. Kim, S. Deppe, A. Abrahani, D.S. Luciani, J.D. Johnson, and B. Rodrigues AMP-activated protein kinase confers protection against TNF-α-induced cardiac cell death Cardiovasc. Res. 84 2009 42 53
26. M. Konishi, G. Haraguchi, H. Ohigashi, T. Ishihara, K. Saito, Y. Nakano, and M. Isobe Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation Cardiovasc. Res. 89 2011 309 319
27. E.L. Kwak, D.A. Larochelle, C. Beaumont, S.V. Torti, and F.M. Torti Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha J. Biol. Chem. 270 1995 15285 15293
28. F.A. Lopez, and S. Casado Heart failure, redox alterations, and endothelial dysfunction Hypertension 38 2001 1400 1405 (Pubitemid 34033423)
29. A.R. Ludke, A.A. Al-Shudiefat, S. Dhingra, D.S. Jassal, and P.K. Singal A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity Can. J. Physiol. Pharmacol. 87 2009 756 763
30. S. Maruyama, R. Shibata, K. Ohashi, T. Ohashi, H. Daida, K. Walsh, T. Murohara, and N. Ouchi Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism J. Biol. Chem. 286 2011 32790 32800
31. C.F. McTiernan Fighting doxorubicin-induced cardiotoxicity with adiponectin Cardiovasc. Res. 89 2011 262 264
32. C.J. Miranda, H. Makui, R.J. Soares, M. Bilodeau, J. Mui, H. Vali, R. Bertrand, N.C. Andrews, and M.M. Santos Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin Blood 102 2003 2574 2580 (Pubitemid 37193598)
33. H. Mizutani, S. Tada-Oikawa, Y. Hiraku, M. Kojima, and S. Kawanishi Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide Life Sci. 76 2005 1439 1453 (Pubitemid 40164773)
34. S. Omiya, S. Hikoso, Y. Imanishi, A. Saito, O. Yamaguchi, T. Takeda, I. Mizote, T. Oka, M. Taneike, Y. Nakano, Y. Matsumura, K. Nishida, Y. Sawa, M. Hori, and K. Otsu Downregulation of ferritin heavy chain increases labile iron pool, oxidative stress and cell death in cardiomyocytes J. Mol. Cell Cardiol. 46 2009 59 66
35. M.R. Owen, E. Doran, and A.P. Halestrap Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Biochem. J 348 Pt 3 2000 607 614 (Pubitemid 30410251)
36. C.G. Pham, C. Bubici, F. Zazzeroni, S. Papa, J. Jones, K. Alvarez, S. Jayawardena, S.E. De, R. Cong, C. Beaumont, F.M. Torti, S.V. Torti, and G. Franzoso Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species Cell 119 2004 529 542 (Pubitemid 39482352)
37. Romero, S. P.; Andrey, J. L.; Garcia-Egido, A.; Escobar, M. A.; Perez, V.; Corzo, R.; Garcia-Domiguez, G. J.; Gomez, F. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus: a propensity-matched study in the community. Int. J. Cardiol. 10.1016/j.ijcard. 2011.10.141, in press
38. H. Sasaki, H. Asanuma, M. Fujita, H. Takahama, M. Wakeno, S. Ito, A. Ogai, M. Asakura, J. Kim, T. Minamino, S. Takashima, S. Sanada, M. Sugimachi, K. Komamura, N. Mochizuki, and M. Kitakaze Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase Circulation 119 2009 2568 2577
39. D.D. Shah, G.C. Fonarow, and T.B. Horwich Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes J. Card. Fail. 16 2010 200 206
40. T. Simunek, M. Sterba, O. Popelova, M. Adamcova, R. Hrdina, and V. Gersl Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacol. Rep. 61 2009 154 171
41. L. Solskov, B. Lofgren, S.B. Kristiansen, N. Jessen, R. Pold, T.T. Nielsen, H.E. Botker, O. Schmitz, and S. Lund Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration Basic Clin. Pharmacol. Toxicol. 103 2008 82 87 (Pubitemid 351874532)
42. S.M. Swain, and P. Vici The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review J. Cancer Res. Clin. Oncol. 130 2004 1 7 (Pubitemid 38161241)
43. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879 (Pubitemid 36605157)
44. S.M. Swain, F.S. Whaley, M.C. Gerber, M.S. Ewer, and J.R. Bianchine Gams, R. A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy J. Clin. Oncol. 15 1997 1333 1340 (Pubitemid 27167364)
45. G. Takemura, and H. Fujiwara Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management Prog. Cardiovasc. Dis. 49 2007 330 352 (Pubitemid 46295436)
46. F.M. Torti, and S.V. Torti Regulation of ferritin genes and protein Blood 99 2002 3505 3516 (Pubitemid 34534516)
47. K.B. Wallace Doxorubicin-induced cardiac mitochondrionopathy Pharmacol. Toxicol. 93 2003 105 115 (Pubitemid 37108538)
48. P.B. Walter, M.D. Knutson, A. Paler-Martinez, S. Lee, Y. Xu, F.E. Viteri, and B.N. Ames Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats Proc. Natl. Acad. Sci. USA 99 2002 2264 2269 (Pubitemid 34169049)
49. L.R. Wiseman, and C.M. Spencer Dexrazoxane: a review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy Drugs 56 1998 385 403 (Pubitemid 28454265)
50. K.A. Wouters, L.C. Kremer, T.L. Miller, E.H. Herman, and S.E. Lipshultz Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies Br. J. Haematol. 131 2005 561 578 (Pubitemid 43899624)
51. X. Xu, R. Sutak, and D.R. Richardson Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking Mol. Pharmacol 73 2008 833 844 (Pubitemid 351397888)
52. E.T. Yeh, and C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J. Am. Coll. Cardiol. 53 2009 2231 2247